| Field | Row 1 |
|---|---|
| adsh | 0000950170-25-064468 |
| cik | 1674416 |
| name | CRISPR THERAPEUTICS AG |
| sic | 2836 |
| countryba | CH |
| stprba | |
| cityba | ZUG |
| zipba | CH-6300 |
| bas1 | BAARERSTRASSE 14 |
| bas2 | |
| baph | 6173154600 |
| countryma | CH |
| stprma | |
| cityma | ZUG |
| zipma | CH-6300 |
| mas1 | BAARERSTRASSE 14 |
| mas2 | |
| countryinc | CH |
| stprinc | |
| ein | 473173478 |
| former | |
| changed | |
| afs | 1-LAF |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250506 |
| accepted | 2025-05-06 16:10:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | crsp-20250331_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0000950170-25-064468 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 718943000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 309776000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Cash Collateral For Borrowed Securities | 3500000.0000 | USD | 0 | us-gaap/2024 | Balance Sheet Location= Prepaid Expenses And Other Current Assets; | ||
| 0000950170-25-064468 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0300 | CHF | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Common Stock Shares Authorized | 132477166.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Contract With Customer Liability Current | 3021000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Depreciation Depletion And Amortization | 4833000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -115867000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Increase Decrease In Accounts Payable And Accrued Liabilities | 9443000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Increase Decrease In Accounts Payable And Accrued Liabilities | 42998000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Liabilities Current | 119447000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Marketable Securities Current | 1605569000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Net Cash Provided By Used In Operating Activities | 109752000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Nonoperating Income Expense | 13537000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | -3454000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Payments To Acquire Marketable Securities | 200730000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Proceeds From Issuance Of Common Stock | 280745000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Profit Loss | -116591000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-064468 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 504000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Grant; | ||
| 0000950170-25-064468 | 20240331 | Stockholders Equity | -1116291000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-064468 | 20240331 | Stockholders Equity | -62000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000950170-25-064468 | 20250331 | Stockholders Equity | 1829160000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Stockholders Equity | 4135000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-064468 | 20240331 | Stock Issued During Period Value Stock Options Exercised | 23844000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-064468 | 20250331 | Stock Issued During Period Value Stock Options Exercised | 1264000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Stock Purchased During Period Shares Employee Stock Purchase Plan | 16026.0000 | shares | 1 | 0000950170-25-064468 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20250331 | Treasury Stock Value | 62000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 85938720.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 20212000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Accounts Receivable Net Current | 25000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 19405000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 19405000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-064468 | 20250331 | Collaboration Expense | 57500000.0000 | USD | 1 | 0000950170-25-064468 | Counterparty Name= Vertex Pharmaceuticals Incorporated And Its Certain Subsidiaries; | ||
| 0000950170-25-064468 | 20240229 | Common Stock Par Or Stated Value Per Share | 71.5000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0300 | CHF | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Common Stock Shares Authorized | 132477166.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Common Stock Shares Issued | 85912297.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 41000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -134887000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Increase Decrease In Accounts Receivable | -200000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Increase Decrease In Operating Lease Assets And Liabilities | -966000.0000 | USD | 1 | 0000950170-25-064468 | |||
| 0000950170-25-064468 | 20241231 | Stockholders Equity | 1840000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-064468 | 20241231 | Stockholders Equity | 2698000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20250331 | Increase Decrease In Other Operating Liabilities | -10541000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Liabilities And Stockholders Equity | 2242034000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Net Cash Provided By Used In Investing Activities | -97800000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Net Income Loss | -116591000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-064468 | 20250331 | Net Income Loss | -135996000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-064468 | 20240331 | Nonoperating Income Expense | 24720000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -11000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -3465000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-064468 | 20241231 | Prepaid Expense And Other Assets Current | 8306000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Proceeds From Sale And Maturity Of Marketable Securities | 186181000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Property Plant And Equipment Net | 129426000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Research And Development Expense | 62350000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-064468 | 20250331 | Research And Development Expense | 60333000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-064468 | 20241231 | Restricted Cash Noncurrent | 11519000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Shares Outstanding | 85741981.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20240331 | Stockholders Equity | 2658000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20250331 | Stockholders Equity | -1501948000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-064468 | 20250331 | Stockholders Equity | -62000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000950170-25-064468 | 20240331 | Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | 214913.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20240331 | Stock Issued During Period Value New Issues | 132000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20250331 | Accrued Liabilities Current | 84615000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Additional Paid In Capital Common Stock | 3293556000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Additional Paid In Capital Common Stock | 3324314000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Assets Current | 1937132000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 401068000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Accounts Payable Current | 13064000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Accounts Receivable Net Current | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Accumulated Other Comprehensive Income Loss Net Of Tax | 4135000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 20212000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-064468 | 20241231 | Assets | 2242034000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Assets Current | 1867611000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Collaboration Expense | 46966000.0000 | USD | 1 | 0000950170-25-064468 | |||
| 0000950170-25-064468 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0000950170-25-064468 | 20250331 | Common Stock Value | 2721000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Contract With Customer Liability Noncurrent | 12323000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Contract With Customer Liability Noncurrent | 12300000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Vertex Pharmaceuticals Inc; | ||
| 0000950170-25-064468 | 20240331 | Earnings Per Share Diluted | -1.4300 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | General And Administrative Expense | 7551000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-064468 | 20250331 | General And Administrative Expense | 6517000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-064468 | 20240331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -2949000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Net Income Loss | -116591000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-064468 | 20250331 | Net Income Loss | -135996000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-064468 | 20240331 | Operating Expenses | 141091000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Other Assets Noncurrent | 20782000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Other Liabilities Noncurrent | 3444000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Other Noncash Income Expense | 8385000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Other Noncash Income Expense | -2253000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Payments To Acquire Property Plant And Equipment | 206000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Prepaid Expense And Other Assets Current | 12326000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Profit Loss | -135996000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-064468 | 20241231 | Property Plant And Equipment Net | 134093000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Retained Earnings Accumulated Deficit | -1365952000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Collaboration Revenue; | ||
| 0000950170-25-064468 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 865000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Shares Outstanding | 86360924.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20231231 | Stockholders Equity | 1882803000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20231231 | Stockholders Equity | 1913000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-064468 | 20240331 | Stockholders Equity | 3199183000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-064468 | 20250331 | Stock Issued During Period Shares New Issues | 162482.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20250331 | Stock Issued During Period Shares New Issues | 200000.0000 | shares | 1 | us-gaap/2024 | Subsidiary Sale Of Stock= Two Thousand Twenty One At Market Offering; Type Of Arrangement= Sales Agreement With Jefferies L L C; | ||
| 0000950170-25-064468 | 20240331 | Stock Issued During Period Value New Issues | 277147000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Stock Issued During Period Value New Issues | 8637000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Stock Issued During Period Value New Issues | 8632000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-064468 | 20240331 | Stock Issued During Period Value Stock Options Exercised | 22000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20241231 | Taxes Payable Current | 451000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Treasury Stock Common Shares | 170316.0000 | shares | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000950170-25-064468 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 246703000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Cash Collateral For Borrowed Securities | 3513000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20190731 | Common Stock Par Or Stated Value Per Share | 0.0300 | CHF | 0 | us-gaap/2024 | Class Of Stock= Common Shares; Type Of Arrangement= Sales Agreement With Jefferies L L C; | ||
| 0000950170-25-064468 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0300 | CHF | 0 | us-gaap/2024 | Class Of Stock= Common Shares; | ||
| 0000950170-25-064468 | 20250331 | Common Stock Shares Issued | 86531240.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Common Stock Shares Outstanding | 85741981.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Common Stock Shares Outstanding | 86360924.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Contract With Customer Liability Noncurrent | 12323000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Earnings Per Share Basic | -1.5800 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | General And Administrative Expense | 17953000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Income Tax Expense Benefit | 724000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Increase Decrease In Contract With Customer Liability | -824000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Liabilities | 336942000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Marketable Securities Current | 1620101000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Net Cash Provided By Used In Operating Activities | -53947000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Operating Lease Liability Noncurrent | 206405000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Operating Lease Liability Noncurrent | 201852000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | 41000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Other Liabilities Current | 10417000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Other Liabilities Current | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Other Nonoperating Income Expense | 24720000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Payments Of Stock Issuance Costs | 100000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20250331 | Payments To Acquire Equity Securities Fv Ni | 5000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Payments To Acquire Marketable Securities | 326915000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Payments To Acquire Property Plant And Equipment | 721000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 25189000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 504000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-064468 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 865000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-064468 | 20240331 | Share Based Compensation | 19405000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-064468 | 20231231 | Stockholders Equity | 2497000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20250331 | Stockholders Equity | 3324314000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-064468 | 20240331 | Stock Issued During Period Shares Stock Options Exercised | 632683.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20240331 | Stock Issued During Period Value New Issues | 277015000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-064468 | 20240331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 7000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Taxes Payable Current | 1241000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20231231 | Treasury Stock Common Shares | 170316.0000 | shares | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000950170-25-064468 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 81794630.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Liabilities Current | 87782000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Net Cash Provided By Used In Financing Activities | 305934000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Net Cash Provided By Used In Financing Activities | 10588000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Stock Purchased During Period Value Employee Stock Purchase Plan | 653000.0000 | USD | 1 | 0000950170-25-064468 | |||
| 0000950170-25-064468 | 20250331 | Cash And Cash Equivalents At Carrying Value | 235184000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Cash Collateral For Borrowed Securities | 11500000.0000 | USD | 0 | us-gaap/2024 | Credit Facility= Letter Of Credit; | ||
| 0000950170-25-064468 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0000950170-25-064468 | 20250331 | Comprehensive Income Net Of Tax | -133701000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Contract With Customer Liability Current | 3845000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Contract With Customer Liability Current | 0.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Vertex Pharmaceuticals Inc; | ||
| 0000950170-25-064468 | 20250331 | Depreciation Depletion And Amortization | 4736000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Earnings Per Share Basic | -1.4300 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Increase Decrease In Operating Lease Assets And Liabilities | -1151000.0000 | USD | 1 | 0000950170-25-064468 | |||
| 0000950170-25-064468 | 20240331 | Increase Decrease In Other Operating Liabilities | -432000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Liabilities | 309954000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Net Income Loss | -116591000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 2295000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-064468 | 20250331 | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | 2254000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Other Liabilities Noncurrent | 3320000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Proceeds From Issuance Of Common Stock | 8516000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Proceeds From Issuance Of Common Stock | 8700000.0000 | USD | 1 | us-gaap/2024 | Subsidiary Sale Of Stock= Two Thousand Twenty One At Market Offering; Type Of Arrangement= Sales Agreement With Jefferies L L C; | ||
| 0000950170-25-064468 | 20250331 | Retained Earnings Accumulated Deficit | -1501948000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Share Based Compensation | 20212000.0000 | USD | 1 | us-gaap/2024 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-064468 | 20231231 | Stockholders Equity | 2878155000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-064468 | 20240331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 7000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20250331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 15000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Stock Purchased During Period Value Employee Stock Purchase Plan | 653000.0000 | USD | 1 | 0000950170-25-064468 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-064468 | 20250331 | Treasury Stock Common Shares | 170316.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Stock Issued During Period Shares Stock Options Exercised | 39996.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20250331 | Stock Issued During Period Value New Issues | 5000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20250331 | Proceeds From Issuance Of Common Stock | 241900000.0000 | USD | 17 | us-gaap/2024 | Subsidiary Sale Of Stock= Two Thousand Twenty One At Market Offering; Type Of Arrangement= Sales Agreement With Jefferies L L C; | ||
| 0000950170-25-064468 | 20241231 | Accounts Payable Current | 14709000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Accumulated Other Comprehensive Income Loss Net Of Tax | 1840000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Cash And Cash Equivalents At Carrying Value | 707427000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | 317875000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -63073000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Cash Collateral For Borrowed Securities | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Collaboration Expense | 57509000.0000 | USD | 1 | 0000950170-25-064468 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-064468 | 20230531 | Common Stock Par Or Stated Value Per Share | 0.0300 | CHF | 0 | us-gaap/2024 | Class Of Stock= Common Shares; | ||
| 0000950170-25-064468 | 20241231 | Common Stock Value | 2698000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | -11000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Income Tax Expense Benefit | 1109000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | 634000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Liabilities And Stockholders Equity | 2166102000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Operating Income Loss | -140587000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 2295000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 2072000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Research And Development Expense | 76172000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 0.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Collaboration Revenue; | ||
| 0000950170-25-064468 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 865000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Grant; | ||
| 0000950170-25-064468 | 20240331 | Share Based Compensation | 19405000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20231231 | Stockholders Equity | -999700000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-064468 | 20240331 | Stockholders Equity | 2083936000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Stockholders Equity | 1932080000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Stockholders Equity | 3293556000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-064468 | 20241231 | Stockholders Equity | -1365952000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0000950170-25-064468 | 20241231 | Stockholders Equity | -62000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000950170-25-064468 | 20250331 | Stockholders Equity | 2721000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20250331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 15000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20241231 | Accrued Liabilities Current | 41072000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Collaboration Expense | 47000000.0000 | USD | 1 | 0000950170-25-064468 | Counterparty Name= Vertex Pharmaceuticals Incorporated And Its Certain Subsidiaries; | ||
| 0000950170-25-064468 | 20250331 | Contract With Customer Liability Current | 0.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Vertex Pharmaceuticals Inc; | ||
| 0000950170-25-064468 | 20250331 | Earnings Per Share Diluted | -1.5800 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Equity Issuance Costs In Accounts Payable Accrued Expenses And Other Long Term Liabilities | 3219000.0000 | USD | 1 | 0000950170-25-064468 | |||
| 0000950170-25-064468 | 20250331 | General And Administrative Expense | 19296000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Operating Income Loss | -148424000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Operating Lease Liability Current | 17506000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Operating Lease Right Of Use Asset | 143461000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Operating Lease Right Of Use Asset | 140277000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Other Assets Noncurrent | 15829000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -3465000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Other Nonoperating Income Expense | 13537000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Payments Of Stock Issuance Costs | 200000.0000 | USD | 1 | us-gaap/2024 | Award Type= Employee Stock Option; | ||
| 0000950170-25-064468 | 20240229 | Proceeds From Issuance Of Common Stock | 280000000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Proceeds From Sale And Maturity Of Marketable Securities | 237336000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Stock Issued During Period Value Stock Options Exercised | 3000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20240331 | Treasury Stock Common Shares | 170316.0000 | shares | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000950170-25-064468 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 81794630.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Profit Loss | -116591000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Profit Loss | -135996000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Restricted Cash Noncurrent | 11516000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 504000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Share Based Compensation | 20212000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Stockholders Equity | -1552000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0000950170-25-064468 | 20250331 | Stock Issued During Period Value Stock Options Exercised | 1261000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-064468 | 20241231 | Treasury Stock Common Shares | 170316.0000 | shares | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Assets | 2166102000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Cash And Cash Equivalents At Carrying Value | 298257000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Collaboration Expense | 46966000.0000 | USD | 1 | 0000950170-25-064468 | Consolidation Items= Operating Segments; | ||
| 0000950170-25-064468 | 20250331 | Collaboration Expense | 57509000.0000 | USD | 1 | 0000950170-25-064468 | |||
| 0000950170-25-064468 | 20240331 | Comprehensive Income Net Of Tax | -120056000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Equity Issuance Costs In Accounts Payable Accrued Expenses And Other Long Term Liabilities | 4522000.0000 | USD | 1 | 0000950170-25-064468 | |||
| 0000950170-25-064468 | 20250331 | Increase Decrease In Accounts Receivable | -25000000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Increase Decrease In Contract With Customer Liability | -504000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Net Cash Provided By Used In Investing Activities | -19755000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Net Income Loss | -135996000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Operating Expenses | 149289000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20241231 | Operating Lease Liability Current | 17288000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Payments Of Stock Issuance Costs | 600000.0000 | USD | 1 | us-gaap/2024 | Award Type= Employee Stock Option; | ||
| 0000950170-25-064468 | 20240331 | Payments Of Stock Issuance Costs | 3800000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20240331 | Payments To Acquire Equity Securities Fv Ni | 7500000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Research And Development Expense | 72484000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Restricted Cash Noncurrent | 8006000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20231231 | Shares Outstanding | 80044378.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20240331 | Shares Outstanding | 84837610.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20231231 | Stockholders Equity | -62000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000950170-25-064468 | 20240331 | Stock Issued During Period Shares New Issues | 3929610.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20250331 | Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | 396943.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20250331 | Stock Issued During Period Shares Stock Options Exercised | 39996.0000 | shares | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20240331 | Stock Issued During Period Value Stock Options Exercised | 23866000.0000 | USD | 1 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Stock Purchased During Period Shares Employee Stock Purchase Plan | 19522.0000 | shares | 1 | 0000950170-25-064468 | Equity Components= Common Stock; | ||
| 0000950170-25-064468 | 20240331 | Stock Purchased During Period Value Employee Stock Purchase Plan | 764000.0000 | USD | 1 | 0000950170-25-064468 | |||
| 0000950170-25-064468 | 20240331 | Stock Purchased During Period Value Employee Stock Purchase Plan | 764000.0000 | USD | 1 | 0000950170-25-064468 | Equity Components= Additional Paid In Capital; | ||
| 0000950170-25-064468 | 20241231 | Treasury Stock Common Shares | 170316.0000 | shares | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0000950170-25-064468 | 20241231 | Treasury Stock Value | 62000.0000 | USD | 0 | us-gaap/2024 | |||
| 0000950170-25-064468 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 85938720.0000 | shares | 1 | us-gaap/2024 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Increase Decrease In Accounts Receivable | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Accounts Receivable | The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. |
| Stock Issued During Period Value Stock Options Exercised | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, Stock Options Exercised | Value of stock issued as a result of the exercise of stock options. |
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Operating Lease Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Current | Present value of lessee's discounted obligation for lease payments from operating lease, classified as current. |
| Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Revenue from Contract with Customer, Excluding Assessed Tax | Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. |
| Payments To Acquire Equity Securities Fv Ni | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Equity Securities, FV-NI | Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity. |
| Payments To Acquire Property Plant And Equipment | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Property, Plant, and Equipment | The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. |
| Taxes Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Taxes Payable, Current | Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Comprehensive Income Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | C | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. |
| Increase Decrease In Contract With Customer Liability | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Contract with Customer, Liability | Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. |
| Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax | Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Accounts Receivable Net Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Accounts Receivable, after Allowance for Credit Loss, Current | Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. |
| Common Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | |
| Common Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | 0 | 0 | monetary | D | D | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Income Tax Expense Benefit | us-gaap/2024 | 0 | 0 | monetary | D | D | Income Tax Expense (Benefit) | Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. |
| Net Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures | Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. |
| Treasury Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Treasury Stock, Value | The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury. |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Restricted Cash Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Restricted Cash, Noncurrent | Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. |
| Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | I | C | Accumulated Other Comprehensive Income (Loss), Net of Tax | Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Common Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Operating Lease Right Of Use Asset | us-gaap/2024 | 0 | 0 | monetary | I | D | Operating Lease, Right-of-Use Asset | Amount of lessee's right to use underlying asset under operating lease. |
| Other Assets Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Other Assets, Noncurrent | Amount of noncurrent assets classified as other. |
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised | Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised. |
| Equity Issuance Costs In Accounts Payable Accrued Expenses And Other Long Term Liabilities | 0000950170-25-064468 | 1 | 0 | monetary | D | D | Equity Issuance Costs in Accounts Payable, Accrued Expenses, and Other Long Term Liabilities | Equity issuance costs in accounts payable, accrued expenses, and other long term liabilities. |
| Accrued Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accrued Liabilities, Current | Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Depreciation Depletion And Amortization | us-gaap/2024 | 0 | 0 | monetary | D | D | Depreciation, Depletion and Amortization | The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Marketable Securities Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Marketable Securities, Current | Amount of investment in marketable security, classified as current. |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax | Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. |
| Proceeds From Sale And Maturity Of Marketable Securities | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Sale and Maturity of Marketable Securities | The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. |
| Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | us-gaap/2024 | 0 | 0 | shares | D | Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures | Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. | |
| Increase Decrease In Operating Lease Assets And Liabilities | 0000950170-25-064468 | 1 | 0 | monetary | D | D | Increase Decrease In Operating Lease Assets And Liabilities | Increase decrease in operating lease assets and liabilities. |
| Stock Purchased During Period Shares Employee Stock Purchase Plan | 0000950170-25-064468 | 1 | 0 | shares | D | Stock Purchased During Period Shares Employee Stock Purchase Plan | Stock purchased during period shares employee stock purchase plan. | |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Increase Decrease In Other Operating Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Other Operating Liabilities | Amount of increase (decrease) in operating liabilities classified as other. |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense and Other Assets | Amount of increase (decrease) in prepaid expenses, and assets classified as other. |
| Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Nonoperating Income (Expense) | The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). |
| Other Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Other Liabilities, Current | Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer. |
| Other Noncash Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Noncash Income (Expense) | Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. |
| Payments Of Stock Issuance Costs | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments of Stock Issuance Costs | The cash outflow for cost incurred directly with the issuance of an equity security. |
| Profit Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. |
| Cash Collateral For Borrowed Securities | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash Collateral for Borrowed Securities | Carrying amount as of the balance sheet date of cash collateral held for borrowed securities, for which the cash is restricted as to withdrawal or usage. |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Operating Expenses | us-gaap/2024 | 0 | 0 | monetary | D | D | Operating Expenses | Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. |
| Operating Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Other Liabilities Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Other Liabilities, Noncurrent | Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. |
| Prepaid Expense And Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Accounts Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Common Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | General and Administrative Expense | The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | Amount after tax of other comprehensive income (loss) attributable to parent entity. |
| Research And Development Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Stock Issued During Period Shares New Issues | us-gaap/2024 | 0 | 0 | shares | D | Stock Issued During Period, Shares, New Issues | Number of new stock issued during the period. | |
| Additional Paid In Capital Common Stock | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital, Common Stock | Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Commitments And Contingencies | us-gaap/2024 | 0 | 0 | monetary | I | C | Commitments and Contingencies | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Common Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Contract With Customer Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Contract with Customer, Liability, Noncurrent | Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Shares, Outstanding | Number of shares issued which are neither cancelled nor held in the treasury. | |
| Collaboration Expense | 0000950170-25-064468 | 1 | 0 | monetary | D | D | Collaboration Expense | Collaboration Expense |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Contract With Customer Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Contract with Customer, Liability, Current | Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. |
| Earnings Per Share Basic | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Increase Decrease In Accounts Payable And Accrued Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable and Accrued Liabilities | The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. |
| Net Cash Provided By Used In Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Other Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Nonoperating Income (Expense) | Amount of income (expense) related to nonoperating activities, classified as other. |
| Payments To Acquire Marketable Securities | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Marketable Securities | Amount of cash outflow for purchase of marketable security. |
| Proceeds From Issuance Of Common Stock | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Issuance of Common Stock | The cash inflow from the additional capital contribution to the entity. |
| Stock Issued During Period Shares Stock Options Exercised | us-gaap/2024 | 0 | 0 | shares | D | Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period | Number of share options (or share units) exercised during the current period. | |
| Stock Issued During Period Value New Issues | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, New Issues | Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. |
| Operating Lease Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Noncurrent | Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. |
| Property Plant And Equipment Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Property, Plant and Equipment, Net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. |
| Treasury Stock Common Shares | us-gaap/2024 | 0 | 0 | shares | I | Treasury Stock, Common, Shares | Number of previously issued common shares repurchased by the issuing entity and held in treasury. | |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. | |
| Stock Purchased During Period Value Employee Stock Purchase Plan | 0000950170-25-064468 | 1 | 0 | monetary | D | D | Stock Purchased During Period Value Employee Stock Purchase Plan | Stock purchased during period value employee stock purchase plan. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0000950170-25-064468 | 2 | 3 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0000950170-25-064468 | 2 | 4 | BS | 0 | H | Marketable Securities Current | us-gaap/2024 | Marketable securities | 0 |
| 0000950170-25-064468 | 2 | 5 | BS | 0 | H | Accounts Receivable Net Current | us-gaap/2024 | Accounts receivable | 0 |
| 0000950170-25-064468 | 2 | 6 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2024 | Prepaid expenses and other current assets | 0 |
| 0000950170-25-064468 | 2 | 7 | BS | 0 | H | Assets Current | us-gaap/2024 | Total current assets | 0 |
| 0000950170-25-064468 | 2 | 8 | BS | 0 | H | Property Plant And Equipment Net | us-gaap/2024 | Property and equipment, net | 0 |
| 0000950170-25-064468 | 2 | 9 | BS | 0 | H | Restricted Cash Noncurrent | us-gaap/2024 | Restricted cash | 0 |
| 0000950170-25-064468 | 2 | 10 | BS | 0 | H | Operating Lease Right Of Use Asset | us-gaap/2024 | Operating lease assets | 0 |
| 0000950170-25-064468 | 2 | 11 | BS | 0 | H | Other Assets Noncurrent | us-gaap/2024 | Other non-current assets | 0 |
| 0000950170-25-064468 | 2 | 12 | BS | 0 | H | Assets | us-gaap/2024 | Total assets | 0 |
| 0000950170-25-064468 | 2 | 15 | BS | 0 | H | Accounts Payable Current | us-gaap/2024 | Accounts payable | 0 |
| 0000950170-25-064468 | 2 | 16 | BS | 0 | H | Accrued Liabilities Current | us-gaap/2024 | Accrued expenses | 0 |
| 0000950170-25-064468 | 2 | 17 | BS | 0 | H | Contract With Customer Liability Current | us-gaap/2024 | Deferred revenue, current | 0 |
| 0000950170-25-064468 | 2 | 18 | BS | 0 | H | Taxes Payable Current | us-gaap/2024 | Accrued tax liabilities | 0 |
| 0000950170-25-064468 | 2 | 19 | BS | 0 | H | Operating Lease Liability Current | us-gaap/2024 | Operating lease liabilities | 0 |
| 0000950170-25-064468 | 2 | 20 | BS | 0 | H | Other Liabilities Current | us-gaap/2024 | Other current liabilities | 0 |
| 0000950170-25-064468 | 2 | 21 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total current liabilities | 0 |
| 0000950170-25-064468 | 2 | 22 | BS | 0 | H | Contract With Customer Liability Noncurrent | us-gaap/2024 | Deferred revenue, non-current | 0 |
| 0000950170-25-064468 | 2 | 23 | BS | 0 | H | Operating Lease Liability Noncurrent | us-gaap/2024 | Operating lease liabilities, net of current portion | 0 |
| 0000950170-25-064468 | 2 | 24 | BS | 0 | H | Other Liabilities Noncurrent | us-gaap/2024 | Other non-current liabilities | 0 |
| 0000950170-25-064468 | 2 | 25 | BS | 0 | H | Liabilities | us-gaap/2024 | Total liabilities | 0 |
| 0000950170-25-064468 | 2 | 26 | BS | 0 | H | Commitments And Contingencies | us-gaap/2024 | Commitments and contingencies, see Note 7 | 0 |
| 0000950170-25-064468 | 2 | 28 | BS | 0 | H | Common Stock Value | us-gaap/2024 | Common shares, CHF 0.03 nominal value, 132,477,166 shares authorized at March 31, 2025 and at December 31, 2024, 86,531,240 and 85,912,297 shares issued at March 31, 2025 and December 31, 2024, respectively, 86,360,924 and 85,741,981 shares outstanding at March 31, 2025 and December 31, 2024, respectively | 0 |
| 0000950170-25-064468 | 2 | 29 | BS | 0 | H | Treasury Stock Value | us-gaap/2024 | Treasury shares, at cost, 170,316 shares at March 31, 2025 and at December 31, 2024 | 1 |
| 0000950170-25-064468 | 2 | 30 | BS | 0 | H | Additional Paid In Capital Common Stock | us-gaap/2024 | Additional paid-in capital | 0 |
| 0000950170-25-064468 | 2 | 31 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Accumulated deficit | 0 |
| 0000950170-25-064468 | 2 | 32 | BS | 0 | H | Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | Accumulated other comprehensive income | 0 |
| 0000950170-25-064468 | 2 | 33 | BS | 0 | H | Stockholders Equity | us-gaap/2024 | Total shareholders' equity | 0 |
| 0000950170-25-064468 | 2 | 34 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | Total liabilities and shareholders equity | 0 |
| 0000950170-25-064468 | 3 | 1 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2024 | Common stock, par value | 0 |
| 0000950170-25-064468 | 3 | 2 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2024 | Common stock, shares authorized | 0 |
| 0000950170-25-064468 | 3 | 3 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2024 | Common stock, shares issued | 0 |
| 0000950170-25-064468 | 3 | 4 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2024 | Common stock, shares outstanding | 0 |
| 0000950170-25-064468 | 3 | 5 | BS | 1 | H | Treasury Stock Common Shares | us-gaap/2024 | Treasury stock, shares | 0 |
| 0000950170-25-064468 | 4 | 8 | IS | 0 | H | Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | Total revenue | 0 |
| 0000950170-25-064468 | 4 | 10 | IS | 0 | H | Research And Development Expense | us-gaap/2024 | Research and development | 0 |
| 0000950170-25-064468 | 4 | 11 | IS | 0 | H | General And Administrative Expense | us-gaap/2024 | General and administrative | 0 |
| 0000950170-25-064468 | 4 | 12 | IS | 0 | H | Collaboration Expense | 0000950170-25-064468 | Collaboration expense, net | 0 |
| 0000950170-25-064468 | 4 | 13 | IS | 0 | H | Operating Expenses | us-gaap/2024 | Total operating expenses | 0 |
| 0000950170-25-064468 | 4 | 14 | IS | 0 | H | Operating Income Loss | us-gaap/2024 | Loss from operations | 0 |
| 0000950170-25-064468 | 4 | 16 | IS | 0 | H | Other Nonoperating Income Expense | us-gaap/2024 | Other income, net | 0 |
| 0000950170-25-064468 | 4 | 17 | IS | 0 | H | Nonoperating Income Expense | us-gaap/2024 | Total other income, net | 0 |
| 0000950170-25-064468 | 4 | 18 | IS | 0 | H | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | Net loss before income taxes | 0 |
| 0000950170-25-064468 | 4 | 19 | IS | 0 | H | Income Tax Expense Benefit | us-gaap/2024 | Provision for income taxes | 1 |
| 0000950170-25-064468 | 4 | 20 | IS | 0 | H | Net Income Loss | us-gaap/2024 | Net loss | 0 |
| 0000950170-25-064468 | 4 | 21 | IS | 0 | H | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | us-gaap/2024 | Foreign currency translation adjustment | 0 |
| 0000950170-25-064468 | 4 | 22 | IS | 0 | H | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | us-gaap/2024 | Unrealized gain (loss) on marketable securities | 0 |
| 0000950170-25-064468 | 4 | 23 | IS | 0 | H | Comprehensive Income Net Of Tax | us-gaap/2024 | Comprehensive loss | 0 |
| 0000950170-25-064468 | 4 | 24 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2024 | Net loss per common share - basic | 0 |
| 0000950170-25-064468 | 4 | 25 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | Basic weighted-average common shares outstanding | 0 |
| 0000950170-25-064468 | 4 | 26 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Net loss per common share - diluted | 0 |
| 0000950170-25-064468 | 4 | 27 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | Diluted weighted-average common shares outstanding | 0 |
| 0000950170-25-064468 | 5 | 10 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Beginning balance | 0 |
| 0000950170-25-064468 | 5 | 11 | EQ | 0 | H | Shares Outstanding | us-gaap/2024 | Beginning balance, Shares | 0 |
| 0000950170-25-064468 | 5 | 12 | EQ | 0 | H | Treasury Stock Common Shares | us-gaap/2024 | Treasury stock, Beginning balance (in shares) | 0 |
| 0000950170-25-064468 | 5 | 13 | EQ | 0 | H | Stock Issued During Period Value New Issues | us-gaap/2024 | Issuance of common shares, net of issuance costs | 0 |
| 0000950170-25-064468 | 5 | 14 | EQ | 0 | H | Stock Issued During Period Shares New Issues | us-gaap/2024 | Issuance of common shares, net of issuance costs (in shares) | 0 |
| 0000950170-25-064468 | 5 | 15 | EQ | 0 | H | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | us-gaap/2024 | Vesting of restricted shares | 0 |
| 0000950170-25-064468 | 5 | 16 | EQ | 0 | H | Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | us-gaap/2024 | Vesting of restricted shares (in shares) | 0 |
| 0000950170-25-064468 | 5 | 17 | EQ | 0 | H | Stock Issued During Period Value Stock Options Exercised | us-gaap/2024 | Exercise of vested options, net of issuance costs | 0 |
| 0000950170-25-064468 | 5 | 18 | EQ | 0 | H | Stock Issued During Period Shares Stock Options Exercised | us-gaap/2024 | Exercise of vested options, net of issuance costs (in shares) | 0 |
| 0000950170-25-064468 | 5 | 19 | EQ | 0 | H | Stock Purchased During Period Value Employee Stock Purchase Plan | 0000950170-25-064468 | Purchase of common stock under ESPP | 0 |
| 0000950170-25-064468 | 5 | 20 | EQ | 0 | H | Stock Purchased During Period Shares Employee Stock Purchase Plan | 0000950170-25-064468 | Purchase of common stock under ESPP (in shares) | 0 |
| 0000950170-25-064468 | 5 | 21 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | Stock-based compensation expense | 0 |
| 0000950170-25-064468 | 5 | 22 | EQ | 0 | H | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | us-gaap/2024 | Other comprehensive income (loss) | 0 |
| 0000950170-25-064468 | 5 | 23 | EQ | 0 | H | Net Income Loss | us-gaap/2024 | Net Income (Loss) | 0 |
| 0000950170-25-064468 | 5 | 24 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Ending balance | 0 |
| 0000950170-25-064468 | 5 | 25 | EQ | 0 | H | Treasury Stock Common Shares | us-gaap/2024 | Treasury Stock, Ending balance (in shares) | 0 |
| 0000950170-25-064468 | 5 | 26 | EQ | 0 | H | Shares Outstanding | us-gaap/2024 | Ending balance, Shares | 0 |
| 0000950170-25-064468 | 6 | 9 | EQ | 1 | H | Payments Of Stock Issuance Costs | us-gaap/2024 | Issuance costs | 0 |
| 0000950170-25-064468 | 7 | 2 | CF | 0 | H | Profit Loss | us-gaap/2024 | Net loss | 0 |
| 0000950170-25-064468 | 7 | 4 | CF | 0 | H | Depreciation Depletion And Amortization | us-gaap/2024 | Depreciation and amortization | 0 |
| 0000950170-25-064468 | 7 | 5 | CF | 0 | H | Share Based Compensation | us-gaap/2024 | Equity-based compensation | 0 |
| 0000950170-25-064468 | 7 | 6 | CF | 0 | H | Other Noncash Income Expense | us-gaap/2024 | Other non-cash items, net | 1 |
| 0000950170-25-064468 | 7 | 8 | CF | 0 | H | Increase Decrease In Accounts Receivable | us-gaap/2024 | Accounts receivable | 1 |
| 0000950170-25-064468 | 7 | 9 | CF | 0 | H | Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | Prepaid expenses and other assets | 1 |
| 0000950170-25-064468 | 7 | 10 | CF | 0 | H | Increase Decrease In Accounts Payable And Accrued Liabilities | us-gaap/2024 | Accounts payable and accrued expenses | 0 |
| 0000950170-25-064468 | 7 | 11 | CF | 0 | H | Increase Decrease In Contract With Customer Liability | us-gaap/2024 | Deferred revenue | 0 |
| 0000950170-25-064468 | 7 | 12 | CF | 0 | H | Increase Decrease In Operating Lease Assets And Liabilities | 0000950170-25-064468 | Operating lease assets and liabilities | 0 |
| 0000950170-25-064468 | 7 | 13 | CF | 0 | H | Increase Decrease In Other Operating Liabilities | us-gaap/2024 | Other liabilities, net | 0 |
| 0000950170-25-064468 | 7 | 14 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Net cash (used in) provided by operating activities | 0 |
| 0000950170-25-064468 | 7 | 16 | CF | 0 | H | Payments To Acquire Property Plant And Equipment | us-gaap/2024 | Purchase of property, plant and equipment | 1 |
| 0000950170-25-064468 | 7 | 17 | CF | 0 | H | Payments To Acquire Equity Securities Fv Ni | us-gaap/2024 | Investment in equity securities | 1 |
| 0000950170-25-064468 | 7 | 18 | CF | 0 | H | Payments To Acquire Marketable Securities | us-gaap/2024 | Purchases of marketable securities | 1 |
| 0000950170-25-064468 | 7 | 19 | CF | 0 | H | Proceeds From Sale And Maturity Of Marketable Securities | us-gaap/2024 | Maturities of marketable securities | 0 |
| 0000950170-25-064468 | 7 | 20 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2024 | Net cash used in investing activities | 0 |
| 0000950170-25-064468 | 7 | 22 | CF | 0 | H | Proceeds From Issuance Of Common Stock | us-gaap/2024 | Proceeds from issuance of common shares, net of issuance costs | 0 |
| 0000950170-25-064468 | 7 | 23 | CF | 0 | H | Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | us-gaap/2024 | Proceeds from exercise of options and ESPP contributions, net of issuance costs | 0 |
| 0000950170-25-064468 | 7 | 24 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2024 | Net cash provided by financing activities | 0 |
| 0000950170-25-064468 | 7 | 25 | CF | 0 | H | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | Effect of exchange rate changes on cash | 0 |
| 0000950170-25-064468 | 7 | 26 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | (Decrease) increase in cash | 0 |
| 0000950170-25-064468 | 7 | 27 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | Cash, cash equivalents and restricted cash, beginning of period | 0 |
| 0000950170-25-064468 | 7 | 28 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | Cash, cash equivalents and restricted cash, end of period | 0 |
| 0000950170-25-064468 | 7 | 30 | CF | 0 | H | Equity Issuance Costs In Accounts Payable Accrued Expenses And Other Long Term Liabilities | 0000950170-25-064468 | Equity issuance costs in accounts payable, accrued expenses, and other long-term liabilities | 0 |
| 0000950170-25-064468 | 8 | 1 | CF | 1 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0000950170-25-064468 | 8 | 2 | CF | 1 | H | Cash Collateral For Borrowed Securities | us-gaap/2024 | Prepaid expenses and other current assets | 0 |
| 0000950170-25-064468 | 8 | 3 | CF | 1 | H | Restricted Cash Noncurrent | us-gaap/2024 | Restricted cash | 0 |
| 0000950170-25-064468 | 8 | 4 | CF | 1 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | us-gaap/2024 | Cash, cash equivalents and restricted cash at end of period | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |